Avalyn Pharma Inc. Common Stock

NASDAQ: AVLN · Healthcare · Biotechnology

PublicHQ Boston, MA · SuffolkCIK 0001540171Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 46

v0.1 · 5/100 weight · pillars only

↑ market scale, workforce scale · ↓ listing tenure, filing timeliness

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

as of 2026-09-01

Market cap

$1.5B

as of 2026-09-01

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Avalyn Pharma Inc. Common Stock’s financial profile?

Avalyn Pharma Inc. Common Stock has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Damora Therapeutics, Inc.——Tyra Biosciences, Inc.——Bicara Therapeutics Inc. Common Stock——First Tracks Biotherapeutics Inc——ArriVent BioPharma, Inc.——Latigo Biotherapeutics Inc.——

Neighbors

Suffolk →

Vertex Pharmaceuticals Incorporated$12.0B88A American Tower Corporation$935.9M76B+State Street Corporation$13.9B67B NSTAR Electric Company——Toast, Inc.$6.2B67B PTC Inc.$2.7B83B+

Key facts

CEOLyn Baranowski

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, MA

ExchangeNASDAQ: AVLN

Employees55

IPO date2026-04-30

Latest filings

8-K2026-09-16 10-Q2026-08-12 8-K2026-08-12 8-K2026-07-01 8-K2026-06-17 8-K2026-06-03 10-Q2026-06-03 8-K2026-05-01

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.